Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

14.53
-0.8200-5.34%
Pre-market: 14.850.3200+2.20%07:48 EDT
Volume:911.81K
Turnover:13.45M
Market Cap:935.07M
PE:-4.19
High:15.39
Open:15.22
Low:14.49
Close:15.35
52wk High:23.19
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.58
T/O Rate:1.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:2.91
PE(LYR):-3.90

Loading ...

Cullinan Therapeutics Price Target Raised to $42.00/Share from $39.00 by Wedbush

Dow Jones
·
Aug 13

Wedbush Adjusts PT on Cullinan Therapeutics to $42 From $39, Maintains Outperform Rating

MT Newswires Live
·
Aug 13

Cullinan Therapeutics Shares Rise 12.3% Premarket After Lung Cancer Drug Meets Late-Stage Trial Goal

THOMSON REUTERS
·
Aug 13

Cullinan Therapeutics, - Zipalertinib Arm Shows Significant Improvement in Progression-Free Survival with Manageable Safety

THOMSON REUTERS
·
Aug 13

Cullinan Therapeutics, - Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial

THOMSON REUTERS
·
Aug 13

Cullinan Therapeutics, - Taiho Oncology, Taiho Pharmaceutical, Cullinan Therapeutics to Pursue U.S. Regulatory Approval for Zipalertinib Combination

THOMSON REUTERS
·
Aug 13

Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal

Reuters
·
Aug 13

Otsuka Holdings Co., Ltd. - Zipalertinib Plus Chemotherapy Meets Primary Pfs Endpoint in Planned Interim Analysis of Phase 3 Rezilient3 Trial

Reuters
·
Aug 13

Cullinan Says Zipalertinib Plus Chemotherapy Meets PFS Endpoint in Phase 3 Rezilient3 Lung Cancer Trial

Reuters
·
Aug 13

Analysts Are Bullish on These Healthcare Stocks: Mesoblast Limited (MEOBF), Cullinan Management (CGEM)

TIPRANKS
·
Aug 07

Cullinan Maintained at Buy as Advancing Autoimmune and Oncology Pipeline Supports Unchanged $36 Price Target

TIPRANKS
·
Aug 07

Wedbush Adjusts Price Target on Cullinan Therapeutics to $39 From $37, Maintains Outperform Rating

MT Newswires Live
·
Aug 06

Cullinan Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Cullinan Therapeutics Q2 EPS $(0.81) Beats $(0.85) Estimate

Benzinga Earnings
·
Aug 06

Cullinan Therapeutics Q2 Operating Income USD -57.254 Million Vs. IBES Estimate USD -57.1 Million

Reuters
·
Aug 06

Cullinan Q2 FY26 Net Loss Narrows 23.36% to $53.7 Million

Reuters
·
Aug 06

Cullinan Therapeutics Q2 Cash & Investments USD 356 Million

THOMSON REUTERS
·
Aug 06

Cullinan Therapeutics Q2 EPS USD -0.81 VS. Ibes Estimate USD -0.81

THOMSON REUTERS
·
Aug 06

Cullinan Therapeutics Q2 Operating Expenses USD 57.254 Million

THOMSON REUTERS
·
Aug 06

Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 06